Second source of growth quietly turning on: management is adding a new way to grow that does not require winning new dem
The model's full reasoning — Q3 2016 call → NOWe need to determine if management describes gaining a new way to grow that does not depend on persuading new customers to buy, i.e., growth from internal assets, existing customers, etc., and that it is already beginning to work in the current period. The transcript discusses ProTmune, FATE-NK100, ToleraCyte, and iPSC platform. The question is about a new way to grow that draws on something already possessed. For example, expanding product label, broadening eligibility, blinding to support accelerated registration. But is that described as already producing effect? The protocol amendment broadened eligibility to include MDS, CML, CMV negative. That could be seen as selling more to existing customers? Actually it's expanding the addressable patient population, which is more about winning new demand? But it's about broadening the product label, which is internal capability. However, management says enrollment is now open, but they haven't described actual revenue or orders from that yet. They say "enrollment is now open under this enhanced protocol" and "we are currently screening subjects at seven U.S. sites." That is activity, but not yet revenue. The question asks if it is already producing real, observable effect in the recent period — actual additional revenue, orders, usage, pricing, retention, or activity now happening. Screening subjects is activity, but is that growth? It's clinical trial progress, not revenue. The company is a biotech, so growth might be measured in clinical progress. But the question specifically says "growth engine has quietly gained a second cylinder that runs on what the company already possesses rather than on newly won demand." The broadening of eligibility is about expanding the potential market, but it's still about winning new patients (demand) in the future. It's not about internal assets like existing customers. Also, the blinding is to support accelerated registration, which is a regulatory strategy, not a growth source. Another possibility: the iPSC platform is an internal asset that can be used to develop off-the-shelf products, but that is still in development, not yet working. The question asks: "does management describe that the company has recently GAINED A NEW WAY TO GROW THAT DOES NOT DEPEND ON PERSUADING NEW CUSTOMERS TO BUY" — that is, growth from something already inside.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| NMR | Nomura Holdings, Inc. | Q1 2024 | 2023-08-02 | D |
| GS | The Goldman Sachs Group, Inc. | Q2 2023 | 2023-07-19 | C+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| ALGN | Align Technology, Inc. | Q4 2022 | 2023-02-01 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| ARCC | Ares Capital Corporation | Q1 2022 | 2022-04-26 | B |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CRS | Carpenter Technology Corporation | Q4 2021 | 2021-08-01 | A |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| ARKR | Ark Restaurants Corp. | Q1 2016 | 2016-05-13 | B |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
MKTX · Q3 2017 → YESThe question is: Does management describe that the company has recently GAINED A NEW WAY TO GROW THAT DOES NOT DEPEND ON PERSUADING NEW CUSTOMERS TO BUY — something already inside its own walls, and i...YES The transcript shows management describing exactly this dynamic in open trading. Rick notes that “Open trading is increasingly becoming an important distribution channel for dealers and their efforts to increase trading velocity and reduce balance sheet usage,” and that “Our vast network of investors and dealers operating on the open trading platform provide an additive tool of liquidity for dealers to move bonds.” Dealer-initiated open trades hit a new high of 24 % of total volume, and open trading already accounts for 37 % of U.S. high-yield volume, 15 % of high-grade, and 13 % of emerging-market volume. These metrics are presented as current-quarter results (new record participation, 51 % rise in price responses, $56 billion traded, ADV +29 %, transactions +45 %), not as future plans. Management treats this as a meaningful, already-operating growth engine that runs on the company’s existing installed base of liquidity providers and clients rather than on winning new ones. The same logic appears in the micro-lot discussion, where the platform’s existing liquidity is already capturing 23 % share of sub-$250 k trades—greater than all other retail ATS platforms combined—without any new customer acquisition.
ZH · Q3 2021 → YESThe question is: Does management describe that the company has recently GAINED A NEW WAY TO GROW THAT DOES NOT DEPEND ON PERSUADING NEW CUSTOMERS TO BUY — something already inside its own walls, and i...YES The transcript shows management describing exactly this: the joint-creation feature (launched October) lets text creators authorize video creators to use their existing answers as video scripts and share copyrights, turning 1.8 million pieces of already-authorized content into new videos that drive millions of additional views and engagement. They present this 1.8 million figure and the resulting video metrics (e.g., 4 million-view and 2.59 million-view examples) as real, observable effects already occurring in Q3, not future plans. They tie it directly to higher video consumption penetration (37% of DAUs), creator income, and overall community monetization efficiency, framing it as a meaningful new growth engine that runs on the company’s existing content library and creator base rather than solely on acquiring new users. This is presented as already working and central to sustaining the 115% revenue growth and 110% paid-member growth. The answer is therefore YES.
CRS · Q4 2021 → YESThe question is: Does management describe that the company has recently GAINED A NEW WAY TO GROW THAT DOES NOT DEPEND ON PERSUADING NEW CUSTOMERS TO BUY — something already inside its own walls, and i...YES The transcript shows management describing the hot strip mill commissioning and Athens facility as already enabling new revenue streams from existing soft magnetics and aerospace capabilities (e.g., producing for FAA-certified motors and sensors), with these outputs explicitly tied to current-period activity rather than future plans. This represents an internal growth lever—leveraging 100% owned assets and approvals already in place—independent of acquiring new customers, and management presents it as actively contributing to the recovery narrative in the current quarter. While broader backlog and bookings reflect market demand, the specific mill and qualification details are framed as a fresh, self-contained growth mechanism now in operation.